Form 4: MAIA Biotechnology Director Acquires Stock Options

MAIA Biotechnology, Inc. reports that Director Jean-Manasse Theagene acquired 27,258 stock options on March 31, 2026, under the company's 2021 Equity Incentive Plan.

Summary

• Jean-Manasse Theagene, a Director at MAIA Biotechnology, Inc., acquired 27,258 stock options on March 31, 2026.
• These options were granted under the company's 2021 Equity Incentive Plan.
• The options vest 100% on the grant date and are exercisable from March 31, 2026, with an expiration date of March 31, 2036.
• The exercise price for these options is $1.40 per share of common stock.
• Following this transaction, Theagene directly beneficially owns 27,258 shares of common stock underlying these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider option grant rather than a significant financial event or strategic shift.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The options are fully vested and exercisable immediately, providing flexibility to the director.
• The grant is part of an established equity incentive plan, suggesting a structured approach to compensation and alignment with shareholder interests.

Negatives

• The filing only details the acquisition of options, not the actual purchase of shares, so no capital has been deployed by the director yet.
• The exercise price of $1.40 per share indicates a potential target for future share price appreciation.

Risks

• The value of the stock options is directly tied to the future performance of MAIA Biotechnology's stock price.
• If the stock price does not exceed the exercise price of $1.40, the options may expire worthless.
• The equity incentive plan, while standard, dilutes existing shareholder value upon exercise of options.

Future Outlook

The stock options granted are exercisable from March 31, 2026, through March 31, 2036, with an exercise price of $1.40 per share. Their ultimate value is contingent on the company's future stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology sector to align executive interests with long-term shareholder value and to attract and retain talent in a competitive industry.

Stakeholder Impact

• Shareholders: The grant of options represents potential future dilution if exercised. However, it also aligns director incentives with stock price appreciation.
• Employees: The existence of the equity incentive plan may influence overall employee compensation strategies.
• Management: The director gains potential financial upside tied to company performance.

Next Steps

• The director may choose to exercise the stock options at any point between March 31, 2026, and March 31, 2036, provided the stock price is above $1.40.
• The company will continue to operate under its 2021 Equity Incentive Plan for future grants.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Form 4, Stock Options, Insider Trading, Equity Incentive Plan, Director, Beneficial Ownership, SEC Filing